Study Examines How Cannabis Use during Pregnancy Affects Birth
Cannabis use during pregnancy associated with negative effects on birth outcomes.
A study published December 12th, 2023, in the Journal of the American Medical Association looked at how cannabis consumed during pregnancy affected the outcomes of births (1). To establish the importance of the study, which was titled “Cannabis Exposure and Adverse Pregnancy Outcomes Related to Placental Function,” researchers cited the lack of knowledge about how cannabis affects pregnancy, plus the rise in cannabis use among individuals of reproductive age (1).
Researchers from several universities and one laboratory confirmed cannabis exposure during the pregnancies of 9257 participants though frozen urine samples collected during three study visits spaced throughout the trimesters, then analyzed birth outcomes including low birth weight, preterm birth, and stillborn (1). These three birth outcomes were combined into one primary outcome due to their connection to placental function, explained lead study author Torri Metz, obstetrician and associate professor at the University of Utah Health (2).
Of the 610 participants exposed to cannabis, 32.4% were exposed only during the first trimester, and 67.6% were exposed beyond the first trimester (1). Researchers found that the adverse birth outcomes were associated with 25.9% of the exposed group compared to 17.4% in the group that was not exposed (1).
“Looking at any adverse outcome, we saw that people who had stopped use within the first trimester didn’t actually have a statistically significant increased risk [vs.] those who had continued use,” Dr. Metz (3).
The analysis was adjusted for certain characteristics and behaviors, including nicotine use (1).
“In this multicenter cohort, maternal cannabis use ascertained by biological sampling was associated with adverse pregnancy outcomes related to placental dysfunction,” stated the abstract (1). “Cannabis use should be avoided during pregnancy to optimize maternal and neonatal outcomes,” researchers concluded in one of the key points of the study (1).
References
- Metz, T. D.; Allshouse, A. A.; McMillin, G. A.; Greene, T.; Chung, J. H.; Grobman, W. A.; Haas, D. M.; Mercer, B. M.; Parry, S.; Reddy, U. M.; et al. Cannabis exposure and adverse pregnancy outcomes related to placental function. JAMA 2023, 330 (22), 2191 DOI: 10.1001/jama.2023.21146.
- Carroll, L. Marijuana use during pregnancy linked to low birth weight, study finds https://www.nbcnews.com/health/womens-health/marijuana-use-pregnancy-linked-low-birth-weight-study-finds-rcna129083 (accessed Dec 18, 2023).
- Malhi, S. Cannabis use linked to higher risk of poor pregnancy outcomes, study ... https://www.washingtonpost.com/health/2023/12/12/cannabis-use-pregnancy-postpartum-study/ (accessed Dec 18, 2023).
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
